the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic Leukemia

Not yet recruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Acute Lymphoblastic Leukemia
Interventions
RADIATION

TMI

Observing the efficacy and safety of allogeneic hematopoietic stem cell transplantation in treating adult acute lymphoblastic leukemia with a conditioning regimen including total marrow irradiation (TMI) in individuals aged 16 years and older: Primary Exploratory Endpoint: Event-free survival at 1 year post allogeneic hematopoietic stem cell transplantation (EFS).

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06461091 - the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter